Q-omics provides the consensus-scored MTCYBP23 profile across patient tissues and cancer cell-line models. MTCYBP23 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MTCYBP23 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, MTCYBP23 RNA expression shows 10,346 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight CESC, LUSC, and LUAD as cancer lineages where MTCYBP23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP23 survival associations across molecular data types. MTCYBP23 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP23 RNA expression–survival associations across cancer types. High MTCYBP23 expression shows unfavorable associations in CESC, KIRC, THYM, LUSC, SKCM and STAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MTCYBP23 RNA expression.
This table summarizes MTCYBP23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP23 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BLCA. The LUSC box plot shows higher MTCYBP23 RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p < 0.001).
This table shows molecular features associated with MTCYBP23 in patient tissues and cancer cell lines. In patient samples, MTCYBP23 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
